NCT05792917View on ClinicalTrials.gov

Bioequivalence Study of Tafolecimab Injections in Chinese Healthy Male Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

166

Participants

Timeline

Start Date

March 6, 2023

Primary Completion Date

March 26, 2023

Study Completion Date

August 4, 2023

Conditions
Healthy Male Subjects
Interventions
DRUG

tafolecimab (a modified manufacturing process)

450mg，SC，single dose

DRUG

tafolecimab (a original manufacturing process)

450mg，SC，single dose

Trial Locations (1)

Unknown

Aerospace Center Hospital, Beijing

All Listed Sponsors
lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY